LDL-C Goal Attainment and LDL-C Reductions

When it comes to lowering LDL cholesterol, your patients at increased risk may need aggressive treatment to achieve their LDL-C goals.

In this section, you can review LDL cholesterol reduction results and LDL cholesterol goal attainment results from comparative clinical trials in which CRESTOR® (rosuvastatin) was used as an adjunct to diet in adult patients starting statin therapy. The usual starting dose of CRESTOR is 10 mg to 20 mg. CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg.[1a]

For detailed comparative clinical trial data on LDL-C goal attainment or LDL-C reductions, click on the appropriate tab below.

Click on the "+" and "—" signs to expand and collapse the clinical information.

LDL-C Goal Attainment

High-risk patients (%) achieving NCEP ATP III LDL-C goal <100 mg/dL[2a]

At 6 weeks, 53% of 498 CRESTOR patients on 10 mg dose[*] and 28% of 510 Lipitor® Patients on 10 mg dose achieved the NCEP ATP III LDL-C goal <100 mg/dL. (* ^ P value is less than .001 vs atorvastatin during same time point. Adapted from Faergeman et al.)

At 12 weeks, 74% of 492 CRESTOR patients on 20 mg dose [*] and 48% of 494 Lipitor® patients on 20 mg dose achieved the NCEP ATP III LDL-C goal <100 mg/dL. (*^ P value is less than .001 vs atorvastatin during same time point. Adapted from Faergeman et al.)

At 18 weeks, 81% of 480 CRESTOR patients on 40 mg dose [*] and 65% of 483 Lipitor® patients on 40 mg dose achieved the NCEP ATP III LDL-C goal <100 mg/dL.(*^ P value is less than .001 vs atorvastatin during same time point. Adapted from Faergeman et al.)

At 24 weeks, 84% of 464 CRESTOR patients [*] on a 40 mg dose and 75% of 476 Lipitor® patients on 80 mg dose achieved the NCEP ATP III LDL-C goal <100 mg/dL. (*^ P value is less than .001 vs atorvastatin during same time point. Adapted from Faergeman et al.)

Please note that CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg.

Mean baseline LDL-C: 188 mg/dL to 189 mg/dL.

Adapted from Faergeman et al.

TRIAL DESCRIPTION:

Adapted from the ECLIPSE trial [2b], [3a]. ECLIPSE was a 24-week, open-label, randomized, multicenter, forced-titration, parallel-group trial comparing the efficacy and safety of CRESTOR and atorvastatin in 1036 patients with hypercholesterolemia and CHD, 10-year CHD risk score >20% (CHD risk equivalent), or clinical evidence of atherosclerosis. Following a 6-week dietary lead-in period, patients were randomized to receive CRESTOR 10 mg or atorvastatin 10 mg for 6 weeks. Doses were force-titrated at 6-week intervals until maximum doses were achieved. Statistical comparisons were not made across the dose range, only across the same time period. The primary end point was percentage of patients achieving NCEP ATP III LDL-C goal of <100 mg/dL at Week 24. During the course of this study, the NCEP ATP III guidelines were updated to include an optional LDL-C goal of <70 mg/dL for very high-risk patients. Analysis of this goal was added to the statistical analysis plan before unblinding of the study data.

REFERENCES:

2. 2a 2b Faergeman O, Hill L, Windler E, et al; ECLIPSE Study Investigators. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology. 2008;111(4):219-228.

Very high-risk patients (%) achieving NCEP ATP III LDL-C optional goal <70 mg/dL[†] [2a] [3a]

At 6 weeks, 8% of 398 CRESTOR patients[‡] on 10 mg dose and 2% of 386 Lipitor® patients on 10 mg dose achieved the updated NCEP ATP III LDL-C optional goal <70 mg/dL. (‡ ^ P value is less than .001 vs atorvastatin during same time point. Adapted from Faergeman et al.)

At 12 weeks, 24% of 399 CRESTOR patients[‡] on 20 mg dose and 5% of 375 Lipitor® patients on 20 mg dose achieved the updated NCEP ATP III LDL-C optional goal <70 mg/dL. (‡ ^ P value is less than .001 vs atorvastatin during same time point. Adapted from Faergeman et al.)

At 18 weeks, 37% of 386 CRESTOR patients[‡] on 40 mg dose and 12% of 366 Lipitor® patients on 40 mg dose achieved the updated NCEP ATP III LDL-C optional goal <70 mg/dL. (‡ ^ P value is less than .001 vs atorvastatin during same time point. Adapted from Faergeman et al.)

At 24 weeks, 38% of 379 CRESTOR patients[‡] on 40 mg dose and 20% of 361 Lipitor® patients on an 80 mg dose achieved the updated NCEP ATP III LDL-C optional goal <70 mg/dL. (‡ ^ P value is less than .001 vs atorvastatin during same time point. Adapted from Faergeman et al.)

† ^ According to the third report of the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III) update, the optional LDL-C goal is <70 mg/dL for very high-risk patients.[4]

Please note that CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg.

Adapted from Faergeman et al.

TRIAL DESCRIPTION:

Adapted from the ECLIPSE trial.[2b], [3b] ECLIPSE was a 24-week, open-label, randomized, multicenter, forced-titration, parallel-group trial comparing the efficacy and safety of CRESTOR and atorvastatin in 1036 patients with hypercholesterolemia and CHD, 10-year CHD risk score >20% (CHD risk equivalent), or clinical evidence of atherosclerosis. Following a 6-week dietary lead-in period, patients were randomized to receive CRESTOR 10 mg or atorvastatin 10 mg for 6 weeks. Doses were force-titrated at 6-week intervals until maximum doses were achieved. Statistical comparisons were not made across the dose range, only across the same time period. The primary end point was percentage of patients achieving NCEP ATP III LDL-C goal of <100 mg/dL at Week 24. During the course of this study, the NCEP ATP III guidelines were updated to include an optional LDL-C goal of <70 mg/dL for very high-risk patients. Analysis of this goal was added to the statistical analysis plan before unblinding of the study data.

REFERENCES:

  • 2. 2a 2b Faergeman O, Hill L, Windler E, et al; ECLIPSE Study Investigators. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology. 2008;111(4):219-228.
  • 3. 3a 3b Faergeman O, Sosef F, Duffield E; on behalf of the ECLIPSE study investigators. Efficacy and tolerability of rosuvastatin and atorvastatin when force titrated in high-risk patients: results from the ECLIPSE study. Poster presented at: 14th International Symposium on Atherosclerosis; June 18-22, 2006; Rome, Italy.
  • 4. ^ Grundy SM, Cleeman JI, Merz CNB, et al; for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.

ATP III LDL-C goal attainment by dose at 6 weeks in patients with hyperlipidemia or mixed dyslipidemia treated with CRESTOR vs other statins[5a]

For a 10 mg dose, 82% of 473 rosuvastatin patients[†], 69% of 633 atorvastatin patients, 51% of 648 simvastatin patients, and 31% of 485 pravastatin patients achieved the ATP III LDL-C goal attainment by dose at 6 weeks. († ^ P value is less than .002 vs simvastatin 10 mg, 20 mg; pravastatin 10 mg, 20 mg, 40 mg; P value is non-significant in CRESTOR 10 mg vs atorvastatin 10 mg, 20 mg, 40 mg; simvastatin 40 mg.)

For a 20 mg dose, 89% of 473 rosuvastatin patients[§], 75% of 633 atorvastatin patients, 63% of 648 simvastatin patients, and 44% of 485 pravastatin patients achieved the ATP III LDL-C goal attainment by dose at 6 weeks. (§^ P value is less than .002 vs simvastatin 40 mg; pravastatin 40 mg; P value is non-significant in CRESTOR 20 mg vs atorvastatin 40 mg, 80 mg; simvastatin 80 mg.)

For a 40 mg dose, 89% of 473 rosuvastatin patients[§], 85% of 633 atorvastatin patients, 66% of 648 simvastatin patients, and 55% of 485 pravastatin patients achieved the ATP III LDL-C goal attainment by dose at 6 weeks. (§^ P value is less than .002 vs simvastatin 40 mg; pravastatin 40 mg; P value is non-significant in CRESTOR 40 mg vs atorvastatin 40 mg, 80 mg; simvastatin 80 mg.)

For an 80 mg dose, 82% of 633 atorvastatin patients, and 82% of 485 pravastatin patients achieved the ATP III LDL-C goal attainment by dose at 6 weeks.

*LDL-C goals: <100 mg/dL for patients with coronary heart disease (CHD), CHD risk equivalents, or multiple risk factors that conferred a 10-year CHD risk of >20%; <130 mg/dL or <160 mg/dL for patients at lower risk. Mean baseline LDL-C in patients were 187 mg/dL.

TRIAL DESCRIPTION:

Adapted from the STELLAR trial[1], [5b]. STELLAR was a 6-week, multicenter, open-label, randomized, 15-arm trial comparing the efficacy and safety of CRESTOR with atorvastatin, simvastatin, and pravastatin in 2240 patients with hyperlipidemia or mixed dyslipidemia. The primary end point was percentage change from baseline in LDL-C at Week 6. The study performed the following dose comparisons: CRESTOR 10 mg vs atorvastatin 10 mg, 20 mg, and 40 mg, simvastatin 10 mg, 20 mg, and 40 mg, and pravastatin 10 mg, 20 mg, and 40 mg; CRESTOR 20 mg vs atorvastatin 20 mg, 40 mg, and 80 mg, simvastatin 20 mg, 40 mg, and 80 mg, and pravastatin 20 mg and 40 mg; and CRESTOR 40 mg vs atorvastatin 40 mg and 80 mg, simvastatin 40 mg and 80 mg, and pravastatin 40 mg. Secondary end points included achievement of NCEP ATP III goal.

REFERENCES:
  • 1. ^ CRESTOR® (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024.
  • 5. 5a 5b Jones PH, Davidson MH, Stein EA, et al; for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152-160.

Achievement of LDL-C <100 mg/dL[*] vs atorvastatin in patients with hyperlipidemia or mixed dyslipidemia[6a]

At 6 weeks:

53% of 156 CRESTOR patients[†] on a 10 mg dose achieved an LDL-C <100 mg/dL. († ^ P value is less than .002 CRESTOR 10 mg vs atorvastatin 10 mg.)

76% of 160 CRESTOR patients[‡] on a 20 mg dose achieved an LDL-C <100 mg/dL. (‡ ^ P value is less than .002 CRESTOR 20 mg vs atorvastatin 20 mg.)

80% of 157 CRESTOR patients[§] on a 40 mg dose achieved an LDL-C <100 mg/dL. (§ ^ P value is less than .002 CRESTOR 40 mg vs atorvastatin 40 mg.)

18% of 158 atorvastatin patients on a 10 mg dose achieved an LDL-C <100 mg/dL.

44% of 154 atorvastatin patients on a 20 mg dose achieved an LDL-C <100 mg/dL.

60% of 156 atorvastatin patients on a 40 mg dose achieved an LDL-C <100 mg/dL.

70% of 165 atorvastatin patients on an 80 mg dose achieved an LDL-C <100 mg/dL.

* ^ Regardless of risk category.

Mean baseline LDL-C in patients were 187 mg/dL to 194 mg/dL.

TRIAL DESCRIPTION:

Adapted from the STELLAR trial.[1], [5], [6b] STELLAR was a 6-week, multicenter, open-label, randomized, 15-arm trial comparing the efficacy and safety of CRESTOR with atorvastatin, simvastatin, and pravastatin in 2240 patients with hyperlipidemia or mixed dyslipidemia. The primary end point was percentage change from baseline in LDL-C at week 6. The study performed the following dose comparisons: CRESTOR 10 mg vs atorvastatin 10 mg, 20 mg, and 40 mg; CRESTOR 20 mg vs atorvastatin 20 mg, 40 mg, and 80 mg; and CRESTOR 40 mg vs atorvastatin 40 mg and 80 mg. Percentage of patients achieving LDL-C <100 mg/dL was not a prospectively planned analysis.

REFERENCES:

  • 1. ^ CRESTOR® (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024.
  • 5. ^ Jones PH, Davidson MH, Stein EA, et al; for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152-160.
  • 6. 6a 6b McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW; STELLAR Study Group. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin. 2003;19(8):689-698.

Achievement of LDL-C <100 mg/dL[*] vs simvastatin in patients with hyperlipidemia or mixed dyslipidemia[6a]

53% of 156 CRESTOR patients[†] on a 10 mg dose achieved an LDL-C <100 mg/dL. († ^ P value is less than .002 for CRESTOR 10 mg vs simvastatin 10 mg, 20 mg, 40 mg.)

76% of 160 CRESTOR patients[‡] on a 20 mg dose achieved an LDL-C <100 mg/dL. (‡ ^ P value is less than .002 for CRESTOR 20 mg vs simvastatin 20 mg, 40 mg, 80 mg.)

80% of 157 CRESTOR patients[§] on a 40 mg dose achieved an LDL-C <100 mg/dL. (§ ^ P value is less than .002 for CRESTOR 40 mg vs simvastatin 40 mg, 80 mg.)

8% of 165 simvastatin patients on a 10 mg dose achieved an LDL-C <100 mg/dL.

14% of 162 simvastatin patients on a 20 mg dose achieved an LDL-C <100 mg/dL.

28% of 158 simvastatin patients on a 40 mg dose achieved an LDL-C <100 mg/dL.

53% of 163 simvastatin patients on an 80 mg dose achieved an LDL-C <100 mg/dL.

* ^ Regardless of risk category.

The mean baseline LDL-C in patients were 187 mg/dL to 194 mg/dL.

TRIAL DESCRIPTION:

Adapted from the STELLAR trial.[1], [5], [6b] STELLAR was a 6-week, multicenter, open-label, randomized, 15-arm trial comparing the efficacy and safety of CRESTOR with atorvastatin, simvastatin, and pravastatin in 2240 patients with hyperlipidemia or mixed dyslipidemia. The primary end point was percentage change from baseline in LDL-C at week 6. The study performed the following dose comparisons: CRESTOR 10 mg vs simvastatin 10 mg, 20 mg, and 40 mg; CRESTOR 20 mg vs simvastatin 20 mg, 40 mg, and 80 mg; and CRESTOR 40 mg vs simvastatin 40 mg and 80 mg. Percentage of patients achieving LDL-C <100 mg/dL was not a prospectively planned analysis.

REFERENCES:

  • 1. ^ CRESTOR® (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024.
  • 5. ^ Jones PH, Davidson MH, Stein EA, et al; for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152-160.
  • 6. 6a 6b McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW; STELLAR Study Group. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin. 2003;19(8):689-698.

Achievement of LDL-C <100 mg/dL[*] vs pravastatin in patients with hyperlipidemia or mixed dyslipidemia[6a]

53% of 156 CRESTOR patients[†] on a 10 mg dose achieved an LDL-C <100 mg/dL. († ^ P value is less than .002 for CRESTOR 10 mg vs pravastatin 10 mg, 20 mg, 40 mg.)

76% of 160 CRESTOR patients[‡] on a 20 mg dose achieved an LDL-C <100 mg/dL. (‡ ^ P value is less than .002 for CRESTOR 20 mg vs pravastatin 20 mg, 40 mg, 80 mg.)

80% of 157 CRESTOR patients[§] on a 40 mg dose achieved an LDL-C <100 mg/dL. (§ ^ P value is less than .002 for CRESTOR 40 mg vs pravastatin 40 mg, 80 mg.)

1% of 160 pravastatin patients on a 10 mg dose achieved an LDL-C <100 mg/dL.

3% of 164 pravastatin patients on a 20 mg dose achieved an LDL-C <100 mg/dL.

8% of 161 pravastatin patients on a 40 mg dose achieved an LDL-C <100 mg/dL.

* ^ Regardless of risk category.

The mean baseline LDL-C in patients were 187 mg/dL to 194 mg/dL.

TRIAL DESCRIPTION:

Adapted from the STELLAR trial.[1], [5], [6b] STELLAR was a 6-week, multicenter, open-label, randomized, 15-arm trial comparing the efficacy and safety of CRESTOR with atorvastatin, simvastatin, and pravastatin in 2240 patients with hyperlipidemia or mixed dyslipidemia. The primary end point was percentage change from baseline in LDL-C at week 6. The study performed the following dose comparisons: CRESTOR 10 mg vs pravastatin 10 mg, 20 mg, and 40 mg; CRESTOR 20 mg vs pravastatin 20 mg and 40 mg; and CRESTOR 40 mg vs pravastatin 40 mg. Percentage of patients achieving LDL-C <100 mg/dL was not a prospectively planned analysis.

REFERENCES:

  • 1. ^ CRESTOR® (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024.
  • 5. ^ Jones PH, Davidson MH, Stein EA, et al; for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152-160.
  • 6. 6a 6b McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW; STELLAR Study Group. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin. 2003;19(8):689-698.

LDL-C Reductions

Changes in LDL-C by dose in patients with hyperlipidemia or mixed dyslipidemia[1a]-[7a]

Have confidence in CRESTOR to provide LDL-C reductions that are important for your patients

Pravastatin patients on a 10 mg dose at 6 weeks achieved a mean -20% change from baseline in LDL-C.

Pravastatin patients on a 20 mg dose at 6 weeks achieved a mean -24% change from baseline in LDL-C.

Pravastatin patients on a 40 mg dose at 6 weeks achieved a mean -30% change from baseline in LDL-C.

Simvastatin patients on a 10 mg dose at 6 weeks achieved a mean -28% change from baseline in LDL-C.

Simvastatin patients on a 20 mg dose at 6 weeks achieved a mean -35% change from baseline in LDL-C.

Simvastatin patients on a 40 mg dose at 6 weeks achieved a mean -39% change from baseline in LDL-C.

Simvastatin patients on an 80 mg dose at 6 weeks achieved a mean -46% change from baseline in LDL-C.

Atorvastatin patients on a 10 mg dose at 6 weeks achieved a mean -37% change from baseline in LDL-C.

Atorvastatin patients on a 20 mg dose at 6 weeks achieved a mean -43% change from baseline in LDL-C.

Atorvastatin patients on a 40 mg dose at 6 weeks achieved a mean -48% change from baseline in LDL-C.

Atorvastatin patients on an 80 mg dose at 6 weeks achieved a mean -51% change from baseline in LDL-C.

CRESTOR patients[*] on a 10 mg dose at 6 weeks achieved a mean -46% change from baseline in LDL-C. (* ^ P value is less than .002 for CRESTOR 10 mg vs atorvastatin 10 mg; simvastatin 10 mg, 20 mg, 40 mg; pravastatin 10 mg, 20 mg, 40 mg; P value is non-significant in CRESTOR 10 mg vs atorvastatin 20 mg, 40 mg.)

CRESTOR patients[†] on a 20 mg dose at 6 weeks achieved a mean -52% change from baseline in LDL-C. († ^ P value is less than .002 for CRESTOR 20 mg vs atorvastatin 20 mg, 40 mg; simvastatin 20 mg, 40 mg, 80 mg; pravastatin 20 mg, 40 mg; P value is non-significant in CRESTOR 20 mg vs atorvastatin 80 mg.)

CRESTOR patients[‡] on a 40 mg dose at 6 weeks achieved a mean -55% change from baseline in LDL-C. (‡ ^ P value is less than .002 for CRESTOR 40 mg vs atorvastatin 40 mg; simvastatin 40 mg, 80 mg; pravastatin 40 mg; P value is non-significant in CRESTOR 40 mg vs atorvastatin 80 mg.)

In the STELLAR trial, CRESTOR 20 mg reduced LDL-C by 52% at Week 6.[1b], [5a], [7b]

Please note that CRESTOR 40 mg should only be used for those patients not achieving their LDL-C goal with 20 mg.

The mean baseline LDL-C in patients were 187 mg/dL to 194 mg/dL.

The number of patients in each treatment group were:

  • CRESTOR 473 patients
  • Atorvastatin 634 patients
  • simvastatin 648 patients
  • pravastatin 485 patients

TRIAL DESCRIPTION:

Adapted from the STELLAR trial.[1c], [5b] STELLAR was a 6 week, multicenter, open-label, randomized, 15-arm trial comparing the efficacy and safety of CRESTOR with atorvastatin, simvastatin, and pravastatin in 2240 patients with hyperlipidemia or mixed dyslipidemia. The study performed the following dose comparisons: CRESTOR 10 mg vs atorvastatin 10 mg, 20 mg, and 40 mg, simvastatin 10 mg, 20 mg, and 40 mg, and pravastatin 10 mg, 20 mg, and 40 mg; CRESTOR 20 mg vs atorvastatin 20 mg, 40 mg, and 80 mg, simvastatin 20 mg, 40 mg, and 80 mg, and pravastatin 20 mg and 40 mg; and CRESTOR 40 mg vs atorvastatin 40 mg and 80 mg, simvastatin 40 mg and 80 mg, and pravastatin 40 mg. The primary end point was percentage change from baseline in LDL-C at Week 6.

REFERENCES:

  • 1. 1a 1b 1c CRESTOR® (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024.
  • 5. 5a 5b Jones PH, Davidson MH, Stein EA, et al; for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152-160.
  • 7. 7a 7b Data on File, REF-148955, AstraZeneca Pharmaceuticals LP.

Now you have another reason to be confident with the efficacy of CRESTOR

LDL-C reductions with CRESTOR were further supported in the VOYAGER meta-analysis (N=32,258)[4a]

Changes in LDL-C by dose in patients with hyperlipidemia or mixed dyslipidemia (total VOYAGER population)[4b]

More than 2/3 of the patients included in the VOYAGER meta-analysis were categorized as high-risk[§a], [4c]

165 simvastatin patients on a 10 mg dose achieved a least squares mean change of -27% from baseline in LDL-C.

2,929 simvastatin patients on a 20 mg dose achieved a least squares mean change of -33% from baseline in LDL-C.

548 simvastatin patients on a 40 mg dose achieved a least squares mean change of -39% from baseline in LDL-C.

479 simvastatin patients on an 80 mg dose achieved a least squares mean change of -45% from baseline in LDL-C.

7,837 atorvastatin patients on a 10 mg dose of achieved a least squares mean change of -36% from baseline in LDL-C.

3,908 atorvastatin patients on a 20 mg dose achieved a least squares mean change of -41% from baseline in LDL-C.

1,324 atorvastatin patients on a 40 mg dose achieved a least squares mean change of -46% from baseline in LDL-C.

2,072 atorvastatin patients on an 80 mg dose achieved a least squares mean change of -50% from baseline in LDL-C.

670 CRESTOR patients on a 5 mg dose achieved a least squares mean change of -39% from baseline in LDL-C.

11,690 CRESTOR patients on a 10 mg dose achieved a least squares mean change of -44% from baseline in LDL-C.

3,554 CRESTOR patients on a 20 mg dose achieved a least squares mean change of -50% from baseline in LDL-C.

2,983 CRESTOR patients on a 40 mg dose achieved a least squares mean change of -55% from baseline in LDL-C.

The mean baseline LDL-C for entire cohort: 171 mg/dL.

Voyager meta-analysis included 37 randomized, comparative studies of CRESTOR [4d], [5]

  • 26 studies vs atorvastatin
  • 5 studies vs simvastatin
  • 6 studies vs atorvastatin and simvastatin.

The Voyager meta-analysis included:

  • 32,258 total patients
  • 21,656 high-risk[§b] patients
  • 8,859 patients with diabetes[6]

§a §b In the VOYAGER meta-analysis, patients were categorized as high-risk if they had either atherogenic dyslipidemia (triglycerides ≥150 mg/dL and HDL-C <40 mg/dL), documented atherosclerotic cardiovascular disease (coronary artery disease, peripheral arterial disease, carotid arterial disease, or abdominal aortic aneurysm), or diabetes.

TRIAL DESCRIPTION:

Adapted from the VOYAGER meta-analysis.[4e] VOYAGER was an individual patient data meta-analysis of 37 randomized studies comparing rosuvastatin with either atorvastatin or simvastatin. The objective of the analysis was to determine the relationship between increasing statin doses and their incremental ability to lower lipid levels and achieve established treatment goals. Studies were identified in the published literature that fulfilled the following criteria: fixed-dose comparisons of rosuvastatin with either atorvastatin or simvastatin, lipid parameters recorded at baseline and on therapy, individual patient data available, and ≥4 weeks in duration. In the 11 studies in which patients were force-titrated to higher doses at predefined intervals, each period was considered an exposure. The total number of exposures was 38,199 to individual doses of statins among 32,258 patients. For each lipid variable, percentage change was calculated from baseline to the end of each fixed-dose period. Differences in percentage change of lipid parameters between each dose of rosuvastatin and each dose of atorvastatin or simvastatin were calculated using only those trials that directly randomized the treatments being compared.

REFERENCES:

  • 4. 4a 4b 4c 4d 4e Nicholls SJ, Brandrup-Wognsen G, Palmer N, et al. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105:69-76.
  • 5. ^ Data on File, REF-148956, AstraZeneca Pharmaceuticals LP.
  • 6. ^ Karlson BW, Barter PJ, Palmer MK, Lundman P, Nicholls SJ. Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER. Nutr Metab Cardiovasc Dis. 2012;22:697-703.

Changes in LDL-C by dose at 6 weeks in patients with hyperlipidemia or mixed dyslipidemia[1a]-[3a]

Have confidence in CRESTOR to provide LDL-C reductions that are important for your patients

In the STELLAR Trial,

Pravastatin patients on a 10 mg dose at 6 weeks achieved a mean -20% change from baseline in LDL-C.

Pravastatin patients on a 20 mg dose at 6 weeks achieved a mean -24% change from baseline in LDL-C.

Pravastatin patients on a 40 mg dose at 6 weeks achieved a mean -30% change from baseline in LDL-C.

Simvastatin patients on a 10 mg dose at 6 weeks achieved a mean -28% change from baseline in LDL-C.

Simvastatin patients on a 20 mg dose at 6 weeks achieved a mean -35% change from baseline in LDL-C.

Simvastatin patients on a 40 mg dose at 6 weeks achieved a mean -39% change from baseline in LDL-C.

Simvastatin patients on an 80 mg dose at 6 weeks achieved a mean -46% change from baseline in LDL-C.

Atorvastatin patients on a 10 mg dose at 6 weeks achieved a mean -37% change from baseline in LDL-C.

Atorvastatin patients on a 20 mg dose at 6 weeks achieved a mean -43% change from baseline in LDL-C.

Atorvastatin patients on a 40 mg dose at 6 weeks achieved a mean -48% change from baseline in LDL-C.

Atorvastatin patients on an 80 mg dose at 6 weeks achieved a mean -51% change from baseline in LDL-C.

CRESTOR patients [*] on a 10 mg dose at 6 weeks achieved a mean -46% change from baseline in LDL-C. (* ^ P<.002 CRESTOR 10 mg vs atorvastatin 10 mg; simvastatin 10 mg, 20 mg, 40 mg; pravastatin 10 mg, 20 mg, 40 mg; P=NS CRESTOR 10 mg vs atorvastatin 20 mg, 40 mg.)

CRESTOR patients[†] on a 20 mg dose at 6 weeks achieved a mean -52% change from baseline in LDL-C. († ^ P<.002 CRESTOR 20 mg vs atorvastatin 20 mg, 40 mg; simvastatin 20 mg, 40 mg, 80 mg; pravastatin 20 mg, 40 mg; P=NS CRESTOR 20 mg vs atorvastatin 80 mg.)

CRESTOR patients[‡] on a 40 mg dose at 6 weeks achieved a mean -55% change from baseline in LDL-C. (‡ ^ P<.002 CRESTOR 40 mg vs atorvastatin 40 mg; simvastatin 40 mg, 80 mg; pravastatin 40 mg; P=NS CRESTOR 40 mg vs atorvastatin 80 mg.)

In the STELLAR trial, CRESTOR 20 mg reduced LDL-C by 52% at Week 6.[1b], [2a], [3b]

CRESTOR 40 mg should only be used for those patients not achieving their LDL-C goal with 20 mg.

The mean baseline LDL-C in patients were 187 mg/dL to 194 mg/dL.

The number of patients in each treatment group were:

  • CRESTOR 473 patients
  • Atorvastatin 634 patients
  • simvastatin 648 patients
  • pravastatin 485 patients

TRIAL DESCRIPTION:

Adapted from the STELLAR trial.[1c], [2b] STELLAR was a 6-week, multicenter, open-label, randomized, 15-arm trial comparing the efficacy and safety of CRESTOR with atorvastatin, simvastatin, and pravastatin in 2240 patients with hyperlipidemia or mixed dyslipidemia. The study performed the following dose comparisons: CRESTOR 10 mg vs atorvastatin 10 mg, 20 mg, and 40 mg, simvastatin 10 mg, 20 mg, and 40 mg, and pravastatin 10 mg, 20 mg, and 40 mg; CRESTOR 20 mg vs atorvastatin 20 mg, 40 mg, and 80 mg, simvastatin 20 mg, 40 mg, and 80 mg, and pravastatin 20 mg and 40 mg; and CRESTOR 40 mg vs atorvastatin 40 mg and 80 mg, simvastatin 40 mg and 80 mg, and pravastatin 40 mg. The primary end point was percentage change from baseline in LDL-C at Week 6.

REFERENCES:

  • 1. 1a 1b 1c CRESTOR® (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024.
  • 2. 2a 2b Jones PH, Davidson MH, Stein EA, et al; for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152-160.
  • 3. 3a 3b Data on File, REF-148955, AstraZeneca Pharmaceuticals LP.

LDL-C reductions vs atorvastatin in hypercholesterolemic patients with coronary heart disease (CHD), 10-year CHD risk score >20% (CHD risk equivalent), or clinical evidence of atherosclerosis[7a]

At 6 weeks: CRESTOR patients[*] on a 10 mg dose achieved a mean change of -47% from baseline in LDL-C. (* ^ P<.001 CRESTOR 10 mg vs atorvastatin 10 mg; CRESTOR 20 mg vs atorvastatin 20 mg; CRESTOR 40 mg vs atorvastatin 40 mg; CRESTOR 40 mg vs atorvastatin 80 mg.) Atorvastatin patients on a 10 mg dose achieved a mean change of -39% from baseline in LDL-C.

At 12 weeks: CRESTOR patients[*] on a 20 mg dose achieved a mean change of -53% from baseline in LDL-C. (* ^ P<.001 CRESTOR 10 mg vs atorvastatin 10 mg; CRESTOR 20 mg vs atorvastatin 20 mg; CRESTOR 40 mg vs atorvastatin 40 mg; CRESTOR 40 mg vs atorvastatin 80 mg.) Atorvastatin patients on a 20 mg dose achieved a mean change of -45% from baseline in LDL-C.

At 18 weeks: CRESTOR patients[*] on a 40 mg dose achieved a mean change of -57% from baseline in LDL-C. (* ^ P<.001 CRESTOR 10 mg vs atorvastatin 10 mg; CRESTOR 20 mg vs atorvastatin 20 mg; CRESTOR 40 mg vs atorvastatin 40 mg; CRESTOR 40 mg vs atorvastatin 80 mg.) Atorvastatin patients on a 40 mg dose achieved a mean change of -49% from baseline in LDL-C.

At 24 weeks: CRESTOR patients[*] on a 40 mg dose achieved a mean change of -57% from baseline in LDL-C. (* ^ P<.001 CRESTOR 10 mg vs atorvastatin 10 mg; CRESTOR 20 mg vs atorvastatin 20 mg; CRESTOR 40 mg vs atorvastatin 40 mg; CRESTOR 40 mg vs atorvastatin 80 mg.) Atorvastatin patients on an 80 mg dose achieved a mean change of -52% from baseline in LDL-C.

The mean baseline LDL-C in patients were 188 mg/dL to 189 mg/dL.

The number of patients in the treatment groups for Week 6 was:

  • CRESTOR 10 mg 498 patients
  • atorvastatin 10 mg 510 patients

The number of patients in the treatment groups for Week 12 was:

  • CRESTOR 20 mg 492 patients
  • atorvastatin 20 mg 494 patients

The number of patients in the treatment groups for Week 18 was:

  • CRESTOR 40 mg 480 patients
  • atorvastatin 40 mg 483 patients

The number of patients in the treatment groups for Week 24 was:

  • CRESTOR 40 mg 464 patients
  • atorvastatin 80 mg 476 patients

TRIAL DESCRIPTION:

Adapted from the ECLIPSE trial.[7b] ECLIPSE was a 24-week, open-label, randomized, multicenter, forced-titration, parallel-group trial comparing the efficacy and safety of CRESTOR and atorvastatin in 1036 patients with hypercholesterolemia and CHD, 10-year CHD risk score >20% (CHD risk equivalent), or clinical evidence of atherosclerosis. Following a 6-week dietary lead-in period, patients were randomized to receive CRESTOR 10 mg or atorvastatin 10 mg for 6 weeks. Doses were force-titrated at 6-week intervals until maximum doses were achieved. Statistical comparisons were not made across the dose range, only across the same time period. The primary end point was percentage of patients achieving NCEP ATP III LDL-C goal of <100 mg/dL at Week 24.

REFERENCE:

7. 7a 7b Faergeman O, Hill L, Windler E, et al; ECLIPSE Study Investigators. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology. 2008;111(4):219-228.

LDL-C reductions vs atorvastatin in hypercholesterolemic patients with cardiovascular disease (CVD) and low HDL-C[8a]

At 6 weeks: CRESTOR patients[*] on a 10 mg dose achieved a mean change of -44% from baseline in LDL-C. (* ^ P value is less than .05 for CRESTOR 10 mg vs atorvastatin 20 mg.) Atorvastatin patients on a 20 mg dose achieved a mean change of -38% from baseline in LDL-C.

At 12 weeks: CRESTOR patients[†] on a 20 mg dose achieved a mean change of -50% from baseline in LDL-C. († ^ P value is less than .01 for CRESTOR 20 mg vs atorvastatin 40 mg.) Atorvastatin patients on a 40 mg dose achieved a mean change of -45% from baseline in LDL-C.

At 18 weeks: CRESTOR patients[‡] on a 40 mg dose achieved a mean change of -55% from baseline in LDL-C. (‡ ^ P value is less than .0001 for CRESTOR 40 mg vs atorvastatin 80 mg.) Atorvastatin patients on an 80 mg dose achieved a mean change of -48% from baseline in LDL-C.

The mean baseline LDL-C in patients were 139 mg/dL to 143 mg/dL.

The number of patients in the treatment groups were

  • CRESTOR 230 patients
  • Atorvastatin 231 patients

TRIAL DESCRIPTION:

Adapted from the RADAR trial.[8b] RADAR was a randomized, multicenter, open-label, parallel-group, forced-titration trial comparing the efficacy and safety of CRESTOR with atorvastatin in 461 hypercholesterolemic patients with CVD and low HDL-C levels (<40 mg/dL). Patients were randomized to receive CRESTOR 10 mg or atorvastatin 20 mg for 6 weeks. At week 6, doses were increased to CRESTOR 20 mg or atorvastatin 40 mg, and at week 12, doses were increased to CRESTOR 40 mg or atorvastatin 80 mg for an additional 6 weeks. Statistical comparisons were not made across the dose range, only across the same time period (6 weeks vs 6 weeks, 12 weeks vs 12 weeks, 18 weeks vs 18 weeks). The primary end point of RADAR was the percentage change from baseline in LDL-C/HDL-C ratio at 6 weeks. Percentage change from baseline in LDL-C was a tertiary end point.

REFERENCE:

8. Jump up to: 8a 8b Jukema JW, Liem A-H, Dunselman PHJM, van der Sloot JAP, Lok DJA, Zwinderman AH. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Curr Med Res Opin. 2005;21(11):1865-1874.

Next: Slowing Atherosclerosis Progression

SAVINGS ELIGIBILITY

Eligible patients MAY pay as low as $3 for a 30-, 60-, or 90-day supply.[*]

* ^ Subject to eligibility. Restrictions apply.

Learn About Savings Eligibility

Important Safety Information for CRESTOR® (rosuvastatin) Tablets

  • CRESTOR is contraindicated in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels or a known hypersensitivity to any component of this product
  • Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with statins, including CRESTOR. These risks can occur at any dose level, but are increased at the highest dose (40 mg)
  • CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy (eg, age ≥65 years, inadequately treated hypothyroidism, renal impairment). The risk of myopathy during treatment with CRESTOR may be increased in Asian patients and with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), cyclosporine, teriflunomide, enasidenib, capmatinib, fostamatinib, febuxostat, gemfibrozil, tafamidis, darolutamide, regorafenib, atazanavir/ritonavir, lopinavir/ritonavir, simeprevir or combination of sofosbuvir/velpatasvir/voxilaprevir, dasabuvir/ombitasvir/paritaprevir/ritonavir, elbasvir/grazoprevir, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, all combinations with ledipasvir (including ledipasvir/sofosbuvir), colchicine or ticagrelor
  • Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever, and if muscle signs and symptoms persist after discontinuing CRESTOR
  • There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use. IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. Treatment with immunosuppressive agents may be required. Discontinue CRESTOR if IMNM is suspected
  • Increases in serum transaminases have occurred, some persistent. Rare reports of fatal and non-fatal hepatic failure have occurred. Consider testing liver enzymes before initiating therapy and as clinically indicated thereafter. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue CRESTOR
  • CRESTOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of chronic liver disease
  • CRESTOR significantly increased INR in patients receiving coumarin anticoagulants (eg, warfarin). In patients taking coumarin anticoagulants and CRESTOR concomitantly, INR should be determined before starting CRESTOR and frequently enough during early therapy to ensure that no significant alteration of INR occurs
  • Dipstick-positive proteinuria and microscopic hematuria were observed among patients treated with CRESTOR. These findings were more frequent in patients taking CRESTOR 40 mg, though it was generally transient and was not associated with worsening renal function. Although the clinical significance of this finding is unknown, dose reduction should be considered for patients on CRESTOR therapy with unexplained persistent proteinuria and/or hematuria during routine urinalysis testing
  • Increases in HbA1c and fasting serum glucose levels have been reported with statins, including CRESTOR. Based on clinical trial data with CRESTOR, in some instances these increases may exceed the threshold for the diagnosis of diabetes mellitus
  • In the controlled clinical trials database, the most common adverse reactions were headache (3.7%), myalgia (3.1%), abdominal pain (2.6%), asthenia (2.5%), and nausea (2.2%)
  • Rare post-marketing reports of cognitive impairment (eg, memory loss, forgetfulness, amnesia, memory impairment, confusion) have been associated with statin use, including CRESTOR. These reports are generally nonserious and reversible upon statin discontinuation
  • Discontinue CRESTOR when pregnancy is recognized. Alternatively, consider the ongoing therapeutic needs of the individual patient
  • CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg
  • Administer CRESTOR at least 2 hours before aluminum and magnesium hydroxide combination antacids

INDICATIONS

  • To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CV risk factor
  • Adjunct to diet to:
    • reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia
    • reduce LDL-C and slow the progression of atherosclerosis in adults
    • reduce LDL-C in patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH)
  • Adjunct to other LDL-C lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH)
  • Adjunct to diet for the treatment of adults with primary dysbetalipoproteinemia or hypertriglyceridemia

Read full Prescribing Information.

You may report side effects related to AstraZeneca products.

References:

1a 1b 1c 1d 1e 1f 1g 1h 1i CRESTOR® (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024.

  • 1a 1b 1c 1c 1d CRESTOR® (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024.
  • ^ Falk, E; Aarhus University Hospital (Skejby). Pathogenesis of atherosclerosis. Am J Cardiol. 2006;47(8):C7-12.
  • ^ Nissen, S; Cleveland Clinic Foundation. Rationale for a postintervention continuum of care; insights from intravascular ultrasound. Am J Cardiol. 2000;86(4):H12-17.
  • ^ Lexcol® (fluvastatin sodium) [package insert]. East Hanover, New Jersey: Novartis; 2020
  • ^ Mevacor® (lovastatin) [package insert]. Whitehouse Station, New Jersey: Merck & Company, Inc. 2012
  • ^ Pravachol® (pravastatin) [package insert]. Princeton, New Jersey: Bristol-Myers Squibb Company, 2020.
  • ^ Lipitor® (atorvastatin) [package insert]. New York, New York: Pfizer, 2021
  • ^ Livalo® (pitavastatin) [package insert]. Montgomery, AL: Kowa group of companies, 2020.
  • ^ Zocor® (simvastatin) [package insert]. Jersey City, NJ: Organon & Company, 2022
  • ^ Vytorin® (ezetimibe/simvastatin) [package insert]. Jersey City, NJ: Organon & Company, 2022.
  • ^ Lexcol® (fluvastatin sodium) [package insert]. East Hanover, New Jersey: Novartis; 2020
  • ^ Mevacor® (lovastatin) [package insert]. Whitehouse Station, New Jersey: Merck & Company, Inc. 2012
  • ^ Pravachol® (pravastatin) [package insert]. Princeton, New Jersey: Bristol-Myers Squibb Company, 2020.
  • ^ Lipitor® (atorvastatin) [package insert]. New York, New York: Pfizer, 2021
  • ^ Livalo® (pitavastatin) [package insert]. Montgomery, AL: Kowa group of companies, 2020.
  • ^ Zocor® (simvastatin) [package insert]. Jersey City, NJ: Organon & Company, 2022
  • ^ Vytorin® (ezetimibe/simvastatin) [package insert]. Jersey City, NJ: Organon & Company, 2022.
  • ^ Faergeman O, Hill L, Windler E, et al; on behalf of the ECLIPSE Study Investigators. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia. Cardiology. 2008;111(4):219-228.
  • ^ Ballantyne CM, Bertolami M, Hernandez Garcia HR, et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J. 2006;151(5):975.e1-975.e9.
  • ^ Schuster H, Barter PJ, Stender S, et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY I) study. Am Heart J. 2004;147(4):705-713.
  • ^ Jones PH, Davidson MH, Stein EA, et al; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92(2):152-160.
  • ^ CRESTOR® (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024.
  • ^ Betteridge DJ, Gibson JM; ANDROMEDA Study Investigators. Effects of rosuvastatin on lipids, lipoproteins, and apolipoproteins in the dyslipidaemia of diabetes. Diabet Med. 2007;24(5):541-549.
  • ^ Berne C, Siewert-Delle A; URANUS Study Investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol. 2005;4:7.
  • ^ Ferdinand KC, Clark LT, Watson KE, et al; ARIES Study Group. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol. 2006;97(2):229-235.
  • ^ Lloret R, Yčas J, Stein M, Haffner S; STARSHIP Study Group. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial). Am J Cardiol. 2006;98(6):768-773.
  • ^ Data on File, REF-148952, AstraZeneca Pharmaceuticals LP.
  • 11a 11b Data on File, REF-148935, AstraZeneca Pharmaceuticals LP.
  • ^ Guyton AC, Hall JE. Textbook of Medical Physiology. 11th ed. Philadelphia, PA: Elsevier Inc; 2006.
  • ^ Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.
  • ^ National Heart, Lung, and Blood Institute. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final Report. Bethesda, MD: National Institutes of Health; 2002. NIH Publication 02-5215
  • 1a 1b CRESTOR® (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024.
  • ^ Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.
  • ^ Naghavi M, Falk E, Hecht HS, et al; for the SHAPE Task Force. From vulnerable plaque to vulnerable patient—part III: executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol. 2006;98(suppl):2H-15H.
  • ^ Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol. 2006;47(suppl):C7-C12.
  • ^ Crouse JR 3rd, Raichlen JS, Riley WA, et al; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297(12):1344-1353.
  • ^ Data on File, REF-148945, AstraZeneca Pharmaceuticals LP.
  • 1a 1b 1c CRESTOR® (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024.
  • ^ Faergeman O, Hill L, Windler E, et al; ECLIPSE Study Investigators. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology. 2008;111(4):219-228.
  • 3a 3b Faergeman O, Sosef F, Duffield E; on behalf of the ECLIPSE study investigators. Efficacy and tolerability of rosuvastatin and atorvastatin when force titrated in high-risk patients: results from the ECLIPSE study. Poster presented at: 14th International Symposium on Atherosclerosis; June 18-22, 2006; Rome, Italy.
  • Grundy SM, Cleeman JI, Merz CNB, et al; for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
  • ^ Jones PH, Davidson MH, Stein EA, et al; for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152-160.
  • 6a 6b 6c McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW; STELLAR Study Group. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin. 2003;19(8):689-698.
  • ^ Data on File, REF-148955, AstraZeneca Pharmaceuticals LP
  • ^ Nicholls SJ, Brandrup-Wognsen G, Palmer N, et al. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105:69-76.

1a 1b 1c 1d 1e 1f 1g 1h 1i 1j 1k 1l 1m 1n 1o 1p 1q 1r CRESTOR® (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024.

1a 1b 1c 1d1d CRESTOR® (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024.

  • 1a CRESTOR® (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024.
  • 2a Lipitor® (atorvastatin calcium) [prescribing information]. Morgantown, WV: Viatris Specialty LLC, 2024.
  • 3a Faergeman O, Hill L, Windler E, et al; on behalf of the ECLIPSE Study Investigators. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia. Cardiology. 2008;111(4):219-228.
  • 4a Jones PH, Davidson MH, Stein EA, et al; for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152-160.
  • 5a Crouse JR 3rd, Raichlen JS, Riley WA, et al; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297(12):1344-1353.

Lipitor is a registered trademark of Upjohn Manufacturing Ireland Unlimited Company, a Viatris Company.

1a 1b 1c 1d CRESTOR® (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024.

This product information is intended for US Health Care Professionals only.

IMPORTANT SAFETY INFORMATION FOR CRESTOR® (ROSUVASTATIN) TABLETS

 EXPAND